These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices. Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655 [TBL] [Abstract][Full Text] [Related]
25. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer. Cohen DJ; Hochster HS Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S21-7. PubMed ID: 18361803 [TBL] [Abstract][Full Text] [Related]
26. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472 [TBL] [Abstract][Full Text] [Related]
27. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer. Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451 [TBL] [Abstract][Full Text] [Related]
29. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. Cheng AL; Li J; Vaid AK; Ma BB; Teh C; Ahn JB; Bello M; Charoentum C; Chen LT; de Lima Lopes G; Ho GF; Kong HL; Lam KO; Liu TS; Park YS; Sriuranpong V; Sudoyo AW; Wang JY; Zhang J; Zhang SZ; Ciardiello F; Köhne CH; Shaw M; Kim TW Clin Colorectal Cancer; 2014 Sep; 13(3):145-55. PubMed ID: 25209093 [TBL] [Abstract][Full Text] [Related]
30. [A perspective: role of targeted therapy in colon cancer]. Chung HH; Jang BI Korean J Gastroenterol; 2013 Mar; 61(3):128-35. PubMed ID: 23575231 [TBL] [Abstract][Full Text] [Related]
31. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673 [TBL] [Abstract][Full Text] [Related]
33. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. Díaz-Rubio E; Pietrantonio F; de Braud F Oncologist; 2012; 17(11):1426-8. PubMed ID: 23073991 [TBL] [Abstract][Full Text] [Related]
34. Current therapies for advanced colorectal cancer. Aggarwal S; Chu E Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340 [TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Jean GW; Shah SR Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402 [TBL] [Abstract][Full Text] [Related]
36. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566 [TBL] [Abstract][Full Text] [Related]
37. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201 [TBL] [Abstract][Full Text] [Related]
39. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040 [TBL] [Abstract][Full Text] [Related]
40. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]